Anogen的ELISA检测试剂盒在细胞因子风暴的检测和治疗中...
Anogen的ELISA检测试剂盒在细胞因子风暴的检测和治疗中的应用
COVID-19的爆发已经夺去了全世界4000多人的生命，50000多名患者仍处于危急状态。这种疾病的严重性，像许多其他急性呼吸道感染，如SARS和MERS，是由肺部病毒感染引起的促炎细胞因子水平升高引起的。
一、细胞因子风暴：细胞因子是人体免疫系统不可或缺的一部分，但它们也会引发有害的宿主反应，如发烧、疼痛和炎症。
“细胞因子风暴”是指免疫系统局部或全身产生过多的促炎细胞因子，以应对多种感染性和非感染性刺激或物理和化学损伤。在严重急性呼吸综合征(SARS)、H1N1和埃博拉病毒感染爆发期间，患者的高死亡率是细胞因子风暴对身体功能产生负面影响的典型例子。目前，一旦细胞因子风暴爆发，没有抗素或抗病毒药物能够阻止它。
在Anogen，我们认为应对有害的细胞因子风暴是一种新的生物防御策略。 自20世纪90年代以来，我们已开始细胞因子研究，并已开发出数百种杂交瘤，它们产生针对许多重要细胞因子的高特异性和高亲和力单克隆抗体，包括肿瘤坏死因子-α、粒细胞巨噬细胞集落刺激因子、白介素-2、白介素-8、白介素-10、白介素-15、白介素-17、白介素-18和TGF- β。
二、Anogen 相关炎性因子的ELISA 检测试剂盒；
此外，已经开发了三种不同的用于检测多种细胞因子表位的酶联免疫试剂盒，并广泛应用于生物医学研究。
Multiplex Human Cytokine ELISA Kit (Inflammatory)
多重人细胞因子酶联免疫试剂盒(炎性)
Multiplex Human Cytokine ELISA Kit (M1/M2/MDSC Cytokines)
多重人细胞因子酶联免疫试剂盒(M1/M2/MDSC细胞因子)
Multiplex Human Cytokine ELISA Kit (Th1/Th2/Th17)
多重人细胞因子酶联免疫试剂盒(Th1/Th2/Th17)
三、Anogen 细胞因子检测和治疗 抗击SARS 的历史：
在2003年非典爆发期间，Anogen与北京的医院合作，发现患者体内两种促炎细胞因子IL-8(CXCL8)和MCP-1(MCAF /CCL2)显著增加。
2004年，我们开发了抗趋化因子白细胞介素-8 (CXCL8)和单核细胞趋化蛋白-1 (CCL2)的人源化嵌合单克隆抗体，并在美国、欧洲、加拿大和中国获得多项ZL。临床前研究中使用嵌合抗白介素-8抗体预防和治疗急性呼吸窘迫综合征的临床前研究发表在《国际免疫药理学:针对趋化因子CXCL-8(白介素-8)的人源化单克隆抗体》上，可有效预防急性肺损伤。
四、Anogen 致力于细胞因子风暴的检测和相关治疗的研究
我们目前正在开发用于临床的诊断试剂盒，以测量患者体内的细胞因子。同时与抗体治疗进行组合可以使患者能够根据所涉及的特定细胞因子接受个体化治疗。
BioTNT
如果你对其中任何一个感兴趣，请不要犹豫与我联系。我们期待您的来信。
联系单位：BioTNT上海冠泰生物科技有限公司（Anogen 中国总代理）
我们正在寻求合作，进一步开发用于诊断和治疗的细胞因子试剂盒和单克隆抗体。在由COVID-19感染期间致命的细胞因子风暴引发的具有全部并发症的疾病中，这些试剂盒和单克隆抗体应该有利于挽救生命。
为什么是Anogen？
> 90-98%纯化
抗体活性验证
有竞争力的批量价格
定制配方
灵活的定制生产
五、细胞因子过度产生的疾病:
asthmatic reaction | 哮喘反应 | MCP-1, MIP-1a， RANTES |
Acute pulmonary disease | 急性肺病 | IL-8， MCP-1, ENA78， RANTES |
endotoxemia and sepsis | 内毒素血症和败血症 | IL-8， MCP-1, MIP-1a， RANTES |
Eczema and psoriasis | 湿疹和银屑病 | IL-8 |
Rheumatiod arthritis | 风湿性关节炎 | IL-8， MCP-1, ENA78， MIP-1a |
osteoarthritis | 骨关节炎 | MIP-1beta |
Immune comples glomerulonephritis | 免疫复合物肾小球肾炎 | IL-8， MCP-1 |
wound healing site | 伤口愈合部位 | MCP-1，IP-10 |
六、下面是Anogen 的抗体治疗产品
ABCREAM:治疗银屑病的方法
白细胞介素-8是中性粒细胞的有效趋化因子、表皮细胞的生长因子和促血管生成因子。银屑病是一种常见的皮肤病，其特征是鳞屑由快速生长的角质细胞堆积而成，并伴有鳞屑周围的炎症和发红。银屑病组织中的白细胞介素-8水平高达150倍，表明其在发病机制中的作用。
Anogen-Yes生物技术公司是第一家利用抗白介素-8抗体治疗银屑病的公司。我们的ZL技术(ABCREAM)是一种含有白介素-8中和抗体的外用软膏。白介素-8中和抗体阻断介导角质形成细胞异常增殖和分化的白介素-8的活性，并增加病变附近的中性粒细胞浸润以发挥抗炎作用。该软膏在临床试验中被发现是有效的。49%至53.8%的患者在接受阿必利治疗六周后，PASI评分改善超过60%，12.9%至15.3%的患者改善超过90%。
ABCream也可有效治疗其他炎症性皮肤病。初步观察表明，它也可用于治疗湿疹，一种常见的皮肤病。2001年获中国食品药品监督管理局(CFDA)颁发的一类新药证书。
HFMD 和 IL-8
手足口病(HFMD)是一种潜在的威胁生命的疾病，常见于大多数小于5岁的儿童。HFMD与肠道病毒71型(EV71)和柯萨奇病毒A6型(CV-A6)有关，属于肠道病毒属中的微小核糖核酸病毒科。尽管在包括欧洲和北美在内的大多数国家都出现了全球性的疫情，但最大的HFMD疫情却出现在亚太地区，原因不明。HFMD疫情不仅近年来有所增加，更严重的病例也更常见。更糟糕的是，HFMD病毒很可能会产生部分变异。重度HFMD的病死率较高。 高血糖症、前白蛋白和白细胞增多症目前被用于HFMD严重程度的临床预测。然而，它们对HFMD患者既不敏感又无特异性。 已经证明，由EV71或CV-A6感染的免疫细胞释放的细胞因子和趋化因子有助于疾病的严重程度。不受控制的免疫反应导致细胞因子表达异常升高，从而导致炎症、组织损伤、肺水肿和其他病理损伤。这种现象被称为“细胞因子风暴”。 已经证明，由EV71或CV-A6感染的免疫细胞释放的细胞因子和趋化因子有助于疾病的严重程度。不受控制的免疫反应导致细胞因子表达异常升高，导致炎症、组织损伤、肺水肿和其他病理损伤。这种现象被称为“细胞因子风暴”。 最新研究表明，在多种细胞因子中，白细胞介素-2、白细胞介素-4、白细胞介素-6、白细胞介素-8、白细胞介素-10、单核细胞趋化蛋白-1、干扰素-γ、粒细胞集落刺激因子和肿瘤坏死因子-α在肠道病毒感染中增加。白细胞介素-8与HFMD病的严重程度密切相关，它与大量中性粒细胞浸润组织和器官有关。尽管在HFMD患者中白细胞介素-6和白细胞介素-10升高，但与疾病的严重程度无关。因此，白细胞介素-8水平可作为严重肠道病毒感染早期的预测指标。此外，人源化抗白介素-8抗体可预防致命并发症，如脑干脑炎(BE)和肺水肿(PE)，以降低严重HFMD的死亡率。 我们的项目是开发一种新的用于早期预测严重HFMD病的多重细胞因子免疫测定(ELISA)的医疗装置和一种有效的抗IL-8的治疗性人源化抗体。
英文原文：
Cytokines are an integral part of the body’s immune system, but they also trigger adverse host responses such as fever, pain, and inflammation. “Cytokine storm” is a situation that the immune system produces excessive pro-inflammatory cytokines, locally or systemically, in response to a number of infectious and non-infectious stimulants, or physical and chemical damages. The high rate of patient death during the outbreak of severe acute respiratory syndrome (SARS), H1N1, and Ebola virus infection is a typical example of cytokine storm’s ferocity to negatively affect body functions. Currently, no antibiotics or antiviral drugs are able to stop the cytokine storm once it breaks out. At Anogen, we believe that tackling the harmful cytokine storm is a novel strategy of bio-defense.
We have initiated cytokine research since the 1990s and have developed hundreds of hybridomas that produce high specificity and high affinity monoclonal antibodies (mAbs) directed against many important cytokines, including TNF-α, GM-CSF, IL-2, IL-8, IL-10, IL-15, IL-17, IL-18, and TGF- β. In addition, three different ELISA kits for detection of multiple cytokine epitopes have been developed and widely applied to biomedical research.
Multiplex Human Cytokine ELISA Kit (Inflammatory)
Multiplex Human Cytokine ELISA Kit (M1/M2/MDSC Cytokines)
Multiplex Human Cytokine ELISA Kit (Th1/Th2/Th17)
Diseases with over production of cytokines:
ABCREAM: Anogen’s solution to psoriasis治疗银屑病的方法
IL-8 is a potent chemokine for neutrophils, growth factor of epidermal cells, and a pro-angiogenic factor. Psoriasis is a common skin disease characterized by scales that are built up with rapid growing keratinocytes accompanied by inflammation and redness around the scales. IL-8 levels elevate up to 150-fold in psoriatic tissue, suggesting its role in the pathogenesis.
Anogen-Yes Biotech is the first company utilizing anti IL-8 Ab to treat psoriasis. Our proprietary technology (ABCREAM) is a topical ointment containing IL-8 neutralization Ab. IL-8 neutralization Ab blocks the activity of IL-8 which mediates the abnormal proliferation and differentiation of keratinocytes, and increases neutrolphil infiltration in the lesion vicinity to exert the anti-inflammatory effect. The ointment was found to be effective during clinical trial. 49% to 53.8% of patients achieved a greater than 60% improvement and 12.9% to 15.3% of patients achieved a greater than 90% improvement in PASI scores after a six week treatment cycle with ABCream.
ABCream may be effective in treatment of other inflammatory skin conditions as well. Preliminary observations suggest that it may also be used for treatment of eczema, a common skin condition. It was awarded Class I New Drug Certificate issued by China Food and Drug Administration (CFDA) in 2001.
HFMD and IL-8
Hand, foot and mouth disease (HFMD) is a potentially life-threatening illness commmonly seen in children mostly younger than five years of age. HFMD associated with Enterovirus 71 (EV71) and Coxsackievirus A6 (CV-A6), members of the Picornaviridae family in the genus Enterovirus. Although present globally in most countries including Europe and North America, the largest HFMD outbreaks has been seen in the Asia-Pacific area, for unknown reasons. HFMD outbreaks are not only increased in recent years, but more severe cases are also more common. Even worse, the HFMD virus is likely to develop partial variations. The fatality rate of severe HFMD is higher.
Hyperglycemia, Pre-albumin and leukocytosis are currently used for clinical prediction of the severity of HFMD. However, they are both insensitive and nonspecific in HFMD patients.
It has been proved that cytokines and chemokines released by EV71 or CV-A6 infected immune cells contribute to the disease severity. The uncontrolled immune responses result in abnormally elevated expression of cytokines that cause inflammation, tissue damage, pulmonary edema and other pathological damage. This phenomenon is known as "Cytokine Storm".
It has been proved that cytokines and chemokines released by EV71 or CV-A6 infected immune cells contribute to the disease severity. The uncontrolled immune responses result in abnormally elevated expression of cytokines that cause inflammation, tissue damage, pulmonary edema and other pathological damage. This phenomenon is known as "Cytokine Storm".
The latest research showed that among many cytokines, IL-2, IL-4, IL-6, IL-8, IL-10, MCP-1, IFN-γ, GM-CSF and TNF-α increase in enterovirus infection. IL-8 is strongly associated with the severity of HFMD with massive neutrophil infiltration of tissue and organ. IL-6 and IL-10, although elevated in HFMD patients, are not related to the disease severity. Thus, IL-8 level could be used as a predictive marker in the early stages of severe enterovirus infection. In addition, humanized anti-IL-8 antibody may prevent fatal complications such as brainstem encephalitis (BE), and pulmonary edema (PE) to reduce the mortality of severe HFMD.
Our project is to develop a new medical device of multiplex cytokine immuno-assay (ELISA) for early prediction of severe HFMD and an effective therapeutic humanized antibody against IL-8.
